Zealand Pharma Informs That New Data Presented At The World Diabetes Congress Support Flexibility In Timing Of Administration For Lyxumia®

Copenhagen, 5 December 2013 – Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) informs that Sanofi (EURONEXT: SAN and NYSE: SNY) today provided results of a 24-week Phase IIIb clinical study showing that Lyxumia® (lixisenatide) met the primary endpoint of non-inferiority in blood sugar lowering (HbA1c) when administered either before breakfast or before the main meal of the day. These results support that lixisenatide can effectively lower blood sugar at either time of administration.

Help employers find you! Check out all the jobs and post your resume.